国: シンガポール
言語: 英語
ソース: HSA (Health Sciences Authority)
Erlotinib hydrochloride eqv. Erlotinib
ROCHE SINGAPORE PTE. LTD.
L01EB02
100mg
TABLET, FILM COATED
Erlotinib hydrochloride eqv. Erlotinib 100mg
ORAL
Prescription Only
F. Hoffmann-La Roche Ltd (Kaiseraugst) (Primary and Secondary Packager)
ACTIVE
2006-02-10
TARCEVA TM Erlotinib hydrochloride ANTINEOPLASTIC AGENT. 1. P HARMACEUTICAL F ORM Tarceva film-coated tablets 25mg, 100mg, 150mg Tarceva tablet 25mg: Round, biconvex face and straight sides, white film-coated, with ‘T 25’ engraved on one side. Tarceva tablet 100mg: Round, biconvex face and straight sides, white film-coated, with ‘T 100’ engraved on one side. Tarceva tablet 150mg: Round, biconvex face and straight sides, white film-coated, with ‘T 150’ engraved on one side. Qualitative and Quantitative Composition _Active ingredient:_ erlotinib. One film-coated tablet of each strength contains erlotinib hydrochloride, corresponding to 25mg, 100mg and 150mg of erlotinib. For excipients, see section 5.1. 2. C LINICAL P ARTICULARS 2.1 THERAPEUTIC INDICATIONS NON-SMALL CELL LUNG CANCER: Tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations. Tarceva is also indicated as monotherapy for maintenance treatment in patients with locally advanced or metastatic non-small cell lung cancer with stable disease after 4 cycles of standard platinum-based first-line chemotherapy. Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)- negative tumours. PANCREATIC CANCER: Tarceva in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer. 2.2 DOSAGE AND METHOD 完全なドキュメントを読む
1 PLEASE VISIT WWW.ROCHE.COM.SG/PHARMA/TARCEVA FOR A PRINTABLE VERSION OF THIS LEAFLET. TAB-TAR-2022 09-0 TARCEVA TM Erlotinib hydrochloride ANTINEOPLASTIC AGENT. ATC CODE L01EB02 1. P HARMACEUTICAL F ORM Tarceva film-coated tablets 25mg, 100mg, 150mg Tarceva tablet 25mg: Round, biconvex face and straight sides, white film-coated, with ‘T 25’ engraved on one side. Tarceva tablet 100mg: Round, biconvex face and straight sides, white film-coated, with ‘T 100’ engraved on one side. Tarceva tablet 150mg: Round, biconvex face and straight sides, white film-coated, with ‘T 150’ engraved on one side. Qualitative and Quantitative Composition _Active ingredient:_ erlotinib. One film-coated tablet of each strength contains erlotinib hydrochloride, corresponding to 25mg, 100mg and 150mg of erlotinib. For excipients, see section 4.2. 2. C LINICAL P ARTICULARS 2.1 THERAPEUTIC INDICATIONS NON-SMALL CELL LUNG CANCER: Tarceva is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations. Tarceva is also indicated for switch maintenance treatment in patients with locally advanced or metastatic NSCLC with EGFR activating mutations and stable disease after first-line chemotherapy. Tarceva is also indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. No survival benefit or other clinically relevant effects of the treatment have been demonstrated in patients with Epidermal Growth Factor Receptor (EGFR)- negative tumours. PANCREATIC CANCER: Tarceva in combination with gemcitabine is indicated for the first-line treatment of patients with locally advanced, unresectable or metastatic pancreatic cancer. 2.2 DOSAGE AND METHOD OF ADMINISTRATION GENERAL Non-small cell lung cancer: EGFR mutation testing should be performed prior to initiation of Tarceva as first-line or maintenance therapy in patients with locally advanced or metastatic NSC 完全なドキュメントを読む